Moreover, given thatpharmacological modulation of PPAR in cancer cells typically arrests the cellcycle in the G0/G1 phase, combination therapy with a PPAR agonist and an antimitotic antitumoragent deserves careful consideration. The gene discussed is PPARA; the disease is cancer.